Skip to main content

Advertisement

SpringerLink
Log in

Significance of Molecular Identification and Antifungal Susceptibility of Clinically Significant Yeasts and Moulds in a Global Antifungal Surveillance Programme

  • Published:
Mycopathologia Aims and scope Submit manuscript

Abstract

The increasing diversity of opportunistic fungi causing serious invasive fungal infections (IFI) has been documented. Accurate identification (ID) is important in guiding therapy, determining prognosis for IFIs and in epidemiological surveys. We assessed the utility of PCR-based methods for the ID of yeasts and moulds that either were uncommon, failed conventional ID, or represented unusual biochemical or phenotypic profiles of common species. Among 1,790 viable fungal clinical isolates received during the SENTRY Program in 2010, 322 strains from 40 study sites had ID confirmed by molecular methods. Isolates were previously identified in participant institutions. Yeasts that were not confirmed by morphology on CHROMagar, growth at 45 °C (Candida albicans/dubliniensis), or assimilation of trehalose (C. glabrata) as well as non-Candida yeasts and all moulds were amplified and sequenced using primers amplifying one or more of the following genes: ITS, 28S, β-tubulin (Aspergillus spp.), TEF (Fusarium spp.), IGS (Trichosporon spp.). The isolates selected for molecular ID included 149 isolates of Candida species, 77 of Aspergillus species, 73 non-Candida yeasts, and 23 other moulds (a total of 41 different species). Overall, the ID determined by the submitting site was confirmed for 189 isolates (58.7 %): Aspergillus spp. (64.1 % correct); Candida spp. (60.1 % correct); non-Candida yeasts (58.9 % correct); non-Aspergillus moulds (30.4 % correct). Species with high levels of concordance between conventional and molecular ID included A. fumigatus (95.0  %), C. lusitaniae (100 %), C. dubliniensis (92.3 %), C. kefyr (100 %), and C. neoformans (90.2 %). Only 50.0 % of isolates of C. albicans and 59.1 % of C. glabrata selected due to unusual phenotypic or biochemical features were found to be correctly identified by the submitting site. Molecular methods for the identification of fungal pathogens are an important adjunct to the conventional identification of many less common clinically relevant yeasts and moulds including species of Candida with unusual or erroneous phenotypic or biochemical profiles. Molecular confirmation of fungal identification is essential in epidemiological surveys such as SENTRY.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cortez KJ, Roilides E, Quiroz-Telles F, et al. Infections caused by Scedosporium spp. Clin Microbiol Rev. 2008;21:157–97.

    Article  PubMed  CAS  Google Scholar 

  2. Johnson EM. Rare and emerging Candida species. Curr Fungal Infect Rep. 2009;3:152–9.

    Article  Google Scholar 

  3. Miceli MH, Diaz JA, Lee SA. Emerging opportunistic yeast infections. Lancet Infect Dis. 2011;11:142–51.

    Article  PubMed  Google Scholar 

  4. Pfaller MA, Diekema DJ, Merz WG. Infections due to emerging non-Candida, non-Cryptococcus opportunistic yeast pathogens. Curr Fungal Infect Rep. 2007;1:53–64.

    Google Scholar 

  5. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol. 2010;36:1–53.

    Article  PubMed  Google Scholar 

  6. Sutton DA. Rare and emerging agents of hyalohyphomycosis. Curr Fungal Infet Reports. 2008;2:134–142.

    Google Scholar 

  7. Alexander BD, Pfaller MA. Contemporary tools for the diagnosis and management of invasive mycoses. Clin Infect Dis. 2006;43:S15–27.

    Article  CAS  Google Scholar 

  8. Balajee SA, Borman AM, Brandt ME, et al. Sequence-based identification of Aspergillus, Fusarium, and Mucorales species in the clinical mycology laboratory: Where are we and where should we go from here? J Clin Microbiol. 2009;47:877–84.

    Article  PubMed  CAS  Google Scholar 

  9. Linton CJ, Borman AM, Cheung G, et al. Molecular identification of unusual pathogenic yeast isolates by large ribosomal subunit gene sequencing: 2 years of experience at the United kingdom mycology reference laboratory. J Clin Microbiol. 2007;45:1152–8.

    Article  PubMed  CAS  Google Scholar 

  10. Pounder JI, Simmon KE, Barton CA, Hohmann SL, Brandt ME, Petti CA. Discovering potential pathogens among fungi identified as nonsporulating molds. J Clin Microbiol. 2007;45:568–71.

    Article  PubMed  CAS  Google Scholar 

  11. Etienne KA, Gade L, Lockhart SR, et al. Screening of a large global Aspergillus fumigatus species complex collection by using a species-specific microsphere-based Luminex assay. J Clin Microbiol. 2009;47:4171–2.

    Article  PubMed  Google Scholar 

  12. Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Jones RN. Triazole and echinocandin wild-type MIC distributions with epidemiological cutoff values for six uncommon species of Candida. J Clin Microbiol. 2011;49:3800–4.

    Article  PubMed  CAS  Google Scholar 

  13. Cendejas-Bueno E, Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M. Identification of pathogenic rare yeast species in clinical samples: comparison between phenotypical and molecular methods. J Clin Microbiol. 2010;48:1895–9.

    Article  PubMed  CAS  Google Scholar 

  14. Latouche GN, Daniel HM, Lee OC, Mitchell TG, Sorrell TC, Meyer W. Comparison of use of phenotypic and genotypic characteristics for identification of species of the anamorph genus Candida and related teleomorph yeast species. J Clin Microbiol. 1997;35:3171–80.

    PubMed  CAS  Google Scholar 

  15. Meletiadis J, Arabatzis M, Bobola M, et al. Comparative evaluation of three commercial identification systems using common and rare bloodstream yeast isolates. J Clin Microbiol. 2011;49:2722–7.

    Article  PubMed  Google Scholar 

  16. Sanguinetti M, Porta R, Sali M, et al. Evaluation of VITEK 2 and RapID yeast plus systems for yeast species identification: experience at a large clinical microbiology laboratory. J Clin Microbiol. 2007;45:1343–6.

    Article  PubMed  CAS  Google Scholar 

  17. Burton MJ, Shah P, Swiatlo E. Misidentification of Candida parapsilosis as C. famata in a clinical case of vertebral osteomyelitis. Am J Med Sci. 2011;341:71–3.

    Article  PubMed  Google Scholar 

  18. Jensen RH, Arendrup MC. Candida palmioleophila: Characterization of a previously overlooked pathogen and its unique susceptibility profile in comparison with five related species. J Clin Microbiol. 2011;49:549–56.

    Article  PubMed  Google Scholar 

  19. Lockhart SR, Messer SA, Pfaller MA, Diekema DJ. Identification and susceptibility profile of Candida fermentati from a worldwide collection of Candida guilliermondii clinical isolates. J Clin Microbiol. 2009;47:242–4.

    Article  PubMed  Google Scholar 

  20. Lockhart SR, Messer SA, Pfaller MA, Diekema DJ. Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis. J Clin Microbiol. 2008;46:2659–64.

    Article  PubMed  CAS  Google Scholar 

  21. Wang H, Xiao M, Kong F, et al. Accurate and practical identification of 20 Fusarium species by seven-locus sequence analysis and reverse line blot hybridization, and an in vitro antifungal susceptibility study. J Clin Microbiol. 2011;49:1890–8.

    Article  PubMed  Google Scholar 

  22. Borman AM, Linton CJ, Miles SJ, Johnson EM. Molecular identification of pathogenic fungi. J Antimicrob Chemother. 2008;61(Suppl 1):i7–12.

    Article  PubMed  CAS  Google Scholar 

  23. Leaw SN, Chang HC, Sun HF, Barton R, Bouchara JP, Chang TC. Identification of medically important yeast species by sequence analysis of the internal transcribed spacer regions. J Clin Microbiol. 2006;44:693–9.

    Article  PubMed  CAS  Google Scholar 

  24. Gilgado F, Cano J, Gene J, Guarro J. Molecular phylogeny of the Pseudallescheria boydii species complex: proposal of two new species. J Clin Microbiol. 2005;43:4930–42.

    Article  PubMed  CAS  Google Scholar 

  25. O’Donnell K, Sutton DA, Fothergill A, et al. Molecular phylogenetic diversity, multilocus haplotype nomenclature, and in vitro antifungal resistance within the Fusarium solani species complex. J Clin Microbiol. 2008;46:2477–90.

    Article  PubMed  Google Scholar 

  26. CLSI. M27-A3. Reference method for broth dilution antifungal susceptibility testing of yeasts. 3rd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.

  27. Pfaller MA, Andes D, Arendrup MC, et al. Clinical breakpoints for voriconazole and Candida spp. revisited: Review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis. 2011;70:330–43.

    Article  PubMed  CAS  Google Scholar 

  28. CLSI. M38-A2. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.

  29. CLSI. M27-S3. Reference method for broth dilution antifungal susceptibility testing of yeasts: 3rd Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.

  30. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D. Testing TCSfA. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: Time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat. 2010;13:180–95.

    Article  PubMed  CAS  Google Scholar 

  31. Pfaller MA, Boyken L, Hollis RJ, et al. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J Clin Microbiol. 2010;48:52–6.

    Article  PubMed  CAS  Google Scholar 

  32. Pfaller MA, Diekema DJ, Andes D, et al. Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug resist Updat. 2011;14:164–76.

    Article  PubMed  CAS  Google Scholar 

  33. Pfaller MA, Boyken L, Hollis RJ, et al. Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution. J Clin Microbiol. 2011;49:630–7.

    Article  PubMed  CAS  Google Scholar 

  34. Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn Microbiol Infect Dis. 2011;69:45–50.

    Article  PubMed  CAS  Google Scholar 

  35. Underwood A, Green J. Call for a quality standard for sequence-based assays in clinical microbiology: Necessity for quality assessment of sequences used in microbial identification and typing. J Clin Microbiol. 2011;49:23–6.

    Article  PubMed  Google Scholar 

  36. Howard SJ, Arendrup MC. Acquired antifungal drug resistance in Aspergillus fumigatus: Epidemiology and detection. Med Mycol. 2010;49(Suppl 1):S90–5.

    PubMed  Google Scholar 

Download references

Acknowledgments

The antifungal global surveillance programmes that served as the source of data used in the development of this manuscript was, in part, supported by Pfizer Inc. and Astellas Ltd. We would also like to acknowledge the contributions of the participants in the SENTRY Program.

Author information

Authors and Affiliations

  1. JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA, 52317, USA

    Michael A. Pfaller, Leah N. Woosley, Shawn A. Messer, Ronald N. Jones & Mariana Castanheira

Authors
  1. Michael A. Pfaller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leah N. Woosley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shawn A. Messer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ronald N. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mariana Castanheira
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael A. Pfaller.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 78 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pfaller, M.A., Woosley, L.N., Messer, S.A. et al. Significance of Molecular Identification and Antifungal Susceptibility of Clinically Significant Yeasts and Moulds in a Global Antifungal Surveillance Programme. Mycopathologia 174, 259–271 (2012). https://doi.org/10.1007/s11046-012-9551-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11046-012-9551-x

Keywords

Search

Navigation